odmj
OncoDaily Medical Journal
ODMJ
3067-6444
OncoDaily Medical Journal
US
5677
10.69690/ODMJ-001-1113-5677
Original Research
Acute Lymphoblastic Leukemia/Lymphoma Induction Complications and End-of-Induction MRD Outcomes in Single Advanced Center
Abd
Abdulaziz Wannas
Almojtaba Hematology and Bone Marrow Transplant Center
abdulazizwannas@yahoo.com
Hussein
Allawi Noor
Almojtaba Hematology and Bone Marrow Transplant Center
Mohammed
Amir Fadhil
Almojtaba Hematology and Bone Marrow Transplant Center
Fadhil
Samaher Abdulrazzaq
Almojtaba Hematology and Bone Marrow Transplant Center
Sabhan
Ahmed Hatem
Almojtaba Hematology and Bone Marrow Transplant Center
Muhrij
Entisar Hadi
Almojtaba Hematology and Bone Marrow Transplant Center
Alhoushi
Boshra Abd Alhaleem
Almojtaba Hematology and Bone Marrow Transplant Center
Auda
Jaffar Muhsin
Almojtaba Hematology and Bone Marrow Transplant Center
Mohammed
Fatimah Hashim
Almojtaba Hematology and Bone Marrow Transplant Center
Hadi
Salma Mohammed
Almojtaba Hematology and Bone Marrow Transplant Center
Aljassas
Zahraa Safaa
Almojtaba Hematology and Bone Marrow Transplant Center
Hasan
Wisam Qais
Almojtaba Hematology and Bone Marrow Transplant Center
Jaber
Saif Ali
Almojtaba Hematology and Bone Marrow Transplant Center
Ibrahim
Ali Khaleel
Almojtaba Hematology and Bone Marrow Transplant Center
Shakir
Mohammed Kadhim
Almojtaba Hematology and Bone Marrow Transplant Center
Dagher
Enass Abdul Kareem
Almojtaba Hematology and Bone Marrow Transplant Center
Challab
Ahmed Kadem
Almojtaba Hematology and Bone Marrow Transplant Center
13
11
2025
ODMJ-001-1113-5677
Copyright (c) 2025 OncoDaily Medical Journal
2025
OncoDaily Medical Journal
Acute lymphoblastic leukemia
Cancer
End-of-Induction MRD
Lymphoma
pediatric oncology
production-ready-file-url
[
Madhusoodhan PP, Carroll WL, Bhatla T. Progress and prospects in pediatric leukemia. Curr Probl Pediatr Adolesc Health Care. 2016 Jul;46(7):229-41.
]
[
Jabbour E, Pui CH, Kantarjian H. Progress and innovations in the management of adult acute lymphoblastic leukemia. JAMA Oncol. 2018 Oct 1;4(10):1413-20.
]
[
Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006 Jan 12;354(2):166-78.
]
[
Aricò M, Valsecchi MG, Rizzari C, et al. Long-term results of the AIEOP-ALL-95 trial for childhood acute lymphoblastic leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. J Clin Oncol. 2008 Jan 10;26(2):283-9.
]
[
Akabane H, Logan A. Clinical significance and management of MRD in adults with acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2020 Jul;18(7):413-22.
]
[
Brown PA, Shah B, Advani A, et al. Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021 Sep 20;19(9):1079-109.
]
[
Brüggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006 Feb 1;107(3):1116-23.
]
[
Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017 Jul 13;3(7):e170580.
]
[
Gupta S, Teachey DT, Chen Z, et al. Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group report. Cancer. 2022 May 1;128(9):1863-70.
]
[
Erdmann F, Kaatsch P, Zeeb H, et al. Survival from childhood acute lymphoblastic leukaemia in West Germany: does socio-demographic background matter? Eur J Cancer. 2014 May;50(7):1345-53.
]
[
Pullen J, Shuster JJ, Link M, et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL: a Pediatric Oncology Group (POG) study. Leukemia. 1999 Nov;13(11):1696-707.
]
[
Creutzig U, Büchner T, Sauerland MC, et al. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer. 2008 Feb 1;112(3):562-71.
]
[
Schwartz MS, Muffly LS. Predicting relapse in acute lymphoblastic leukemia. Leuk Lymphoma. 2024 Dec;65(13):1934-40.
]
[
Chandhok NS, Sekeres MA. Measurable residual disease in hematologic malignancies: a biomarker in search of a standard. EClinicalMedicine. 2025 Jul 10;86:103348.
]
[
van der Velden VH, Cazzaniga G, Schrauder A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007 Apr;21(4):604-11.
]
[
Theunissen P, Mejstrikova E, Sedek L, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2017 Jan 19;129(3):347-57.
]
[
van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998 Nov 28;352(9142):1731-8.
]
[
Yilmaz B, Koc A, Dogru O, et al. The results of the modified St Jude Total Therapy XV protocol in the treatment of low- and middle-income children with acute lymphoblastic leukemia. Leuk Lymphoma. 2023 Jul–Aug;64(7):1304-14.
]
[
Dworzak MN, Fröschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002 Mar 15;99(6):1952-8.
]
[
Campana D. Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol. 2009 Jan;46(1):100-6.
]
[
Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008 Apr;22(4):771-82.
]
[
Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013 Jun 1;381(9881):1943-55.
]
[
Afzal S, Ethier MC, Dupuis LL, et al. Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Pediatr Infect Dis J. 2009 Dec;28(12):1064-8.
]
[
O’Connor D, Bate J, Wade R, et al. Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. Blood. 2014 Aug 14;124(7):1056-61.
]
[
Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001 Mar 1;97(5):1211-8.
]
[
Tosur M, Viau-Colindres J, Astudillo M, et al. Medication-induced hyperglycemia: pediatric perspective. BMJ Open Diabetes Res Care. 2020 Jan;8(1):e000801.
]
[
Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev. 2002 Dec;16(4):225-43.
]
[
Handattu K, Sharma LK, Vijayasekharan K, et al. Drug induced diabetes mellitus in pediatric acute lymphoblastic leukemia: approach to diagnosis and management. J Pediatr Hematol Oncol. 2022 Aug 1;44(6):273-9.
]
[
McCormick MC, Sharp E, Kalpatthi R, et al. Hyperglycemia requiring insulin during acute lymphoblastic leukemia induction chemotherapy is associated with increased adverse outcomes and healthcare costs. Pediatr Blood Cancer. 2020 Sep;67(9):e28475.
]
[
Bakk I, Koch T, Stanek J, et al. Steroid-induced hypertension during induction chemotherapy for acute lymphoblastic leukemia in US children’s hospitals. J Pediatr Hematol Oncol. 2018 Jan;40(1):27-30.
]
[
Malhotra P, Kapoor G, Jain S, et al. Incidence and risk factors for hypertension during childhood acute lymphoblastic leukemia therapy. Indian Pediatr. 2018 Oct 15;55(10):877-9.
]
[
Hoshino A, Okuno Y, Migita M, et al. X-linked agammaglobulinemia associated with B-precursor acute lymphoblastic leukemia. J Clin Immunol. 2015 Feb;35(2):108-11.
]
[
Michels N, Boer JM, Enshaei A, et al. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study. Lancet Haematol. 2021 Oct;8(10):e700-10.
]
[
Anestin AS, Lippé S, Robaey P, et al. Psychological risk in long-term survivors of childhood acute lymphoblastic leukemia and its association with functional health status: a PETALE cohort study. Pediatr Blood Cancer. 2018 Nov;65(11):e27356.
]
[
Mertens AC, Gilleland Marchak J. Mental health status of adolescent cancer survivors. Clinical Oncology in Adolescents and Young Adults (COAYA). 2015;5:87-95.
]
[
Marcoux S, Robaey P, Krajinovic M, et al. Predictive factors of internalized and externalized behavioral problems in children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Jun;58(6):971-7.
]
[
Furlong W, Rae C, Feeny D, et al. Health-related quality of life among children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Oct;59(4):717-24.
]
[
Agrawal V, Kayal S, Ganesan P, et al. Chemotherapy delays are associated with inferior outcome in acute lymphoblastic leukemia: a retrospective study from a tertiary cancer center in South India. Indian J Med Paediatr Oncol. 2021;42:5-60.
]
[
Yeoh A, Collins A, Fox K, et al. Treatment delay and the risk of relapse in pediatric acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2017 Feb;34(1):38-42.
]
[
Conter V, Aricò M, Basso G, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia. 2010 Feb;24(2):255-64.
]
[
Schrappe M, Hunger SP, Pui CH, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012 Apr 12;366(15):1371-81.
]
[
Christensen MS, Heyman M, Möttönen M, et al. Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001. Br J Haematol. 2005 Oct;131(1):50-8.
]
[
Meeske KA, Ji L, Freyer DR, et al. Comparative toxicity by sex among children treated for acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2015 Dec;62(12):2140-9.
]
[
Hafez HA, Soliaman RM, Bilal D, et al. Early deaths in pediatric acute leukemia: a major challenge in developing countries. J Pediatr Hematol Oncol. 2019 May;41(4):261-6.
]